SEC Filing Summary: Graphite Bio, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Graphite Bio, Inc. (not LENZ Therapeutics, Inc.) on March 20, 2023. The filing serves to announce the company's financial results for the fiscal year ended December 31, 2022, as detailed in the accompanying press release (Exhibit 99.1).
Key Financial Metrics
The provided text is a cover page and does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release.
Material Changes
No specific material changes or comparative financial data versus the prior period are disclosed in the text of this Form 8-K. The document solely references the issuance of the press release containing the fourth quarter and full-year 2022 results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in the report and the accompanying exhibit shall not be deemed "filed" under Section 18 of the Exchange Act and shall not be incorporated by reference into other SEC filings. No specific guidance, outlook, or risk factors are detailed in the text provided.
Investor Verification Checklist
- Verify the correct registrant name is Graphite Bio, Inc. (Ticker: GRPH), as the input metadata incorrectly listed LENZ Therapeutics, Inc.
- Review Exhibit 99.1 (the press release) for actual financial figures, as they are absent from the Form 8-K text.
- Confirm the company's status as an Emerging Growth Company as indicated by the checkmark in the filing.
- Note that the financial data in the press release is not incorporated by reference into this specific filing.